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Abstract
In GBM, enhancing fraction derived from the initial area under the contrast agent concentration curve (IAUC), EnFIAUC60, correlates with the MRI parameter Ktrans 
(contrast agent transfer coefficient). Thresholding voxels as enhancing when IAUC60>2.5mMol.s (EnFIAUC60>2.5) separates high from low grade glioma. The objectives 
were to evaluate the feasibility of deriving a signal intensity based enhancing fraction (EnFSI), assess its relationship with EnFIAUC60 measures and examine relationships 
with survival in GBM.
30 GBM had pre-operative pre and post-contrast T1-weighted imaging and a T1-DCE-MRI protocol. EnFIAUC60>0 and EnFIAUC60>2.5 were generated from IAUC60 
maps. EnFSI was derived from pre and post-contrast T1-weighted sequences. Bland/Altman plots assessed agreement between EnF measures. A multivariate Cox 
regression analysis examined the prognostic value of EnF measures.
The mean difference between EnFIAUC60>0 and EnFSI was 0.0378 (range -0.112-0.264, std. dev 0.07573) and between EnFIAUC60>2.5 and EnFSI was -0.2492 (range 
-0.6096-0.2416, std. dev 0.2154). EnFSI demonstrated good correlation with both EnFIAUC60>0 and EnFIAUC60>2.5 but was not directly interchangeable with either metric. 
Increased EnFIAUC60>0 was associated with prolonged survival (p=0.008). A non-significant trend was seen with EnFSI (p=0.061).
EnFSI can be derived from conventional imaging and correlates with IAUC60 based metrics. Furthermore, enhancing fraction conveys potential prognostic information 
in GBM.
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Introduction
The potential of enhancing fraction (EnF) in predicting cancer 
outcome was first described in epithelial ovarian carcinoma where 
a CT based metric was found to predict clinical outcome following 
first line chemotherapy [1]. An MRI based measure of EnF has been 
shown to provide clinical information in glioma [2,3]. The commonest 
approach to calculating EnF from MRI is to use the initial area 
under the concentration time curve (IAUC60) derived from dynamic 
contrast enhanced MRI (DCE-MRI) and to measure the proportion 
of voxels within a tumour with a measurable IAUC (> 0 mMol.s) 
[2,3]. The application of a thresholding technique to EnF allows for 
the distinction between low and high grade glioma [3]. EnF has been 
shown to correlate with the established DCE-MRI derived parameters 
vp (in low grade glioma) and Ktrans (in glioblastoma multiforme, GBM)
[2]. The present technique for measuring EnF requires a DCE-MRI 
acquisition, calculation of pixel by pixel contrast concentration time 
course curves providing parametric maps of IAUC60. Although IAUC60 
is considered to be a more reliable, reproducible and robust measure 
than some pharmaco-kinetic modelling parameters such as vp [4], the 
requirement of a DCE-MRI acquisition and post processing analysis 
limits its use in the routine clinical setting. 
Baseline, pre-operative measurements of blood volume (derived 
from both T1 DCE and DSC imaging techniques) and Ktrans (from T1 
DCE) [5-11] have shown potential in predicting survival in GBM. But 
as stated above, these techniques can require lengthy acquisitions and 
complex post processing analysis, which limits their application in the 
clinical setting. To date, the clinical application of these metrics focuses 
predominantly on guiding the surgeon in targeting biopsy, evaluating 
for malignant de-differentiation and attempting to differentiate from 
treatment effect and tumour progression. In a research setting, there 
is some utilisation of these metrics as potential surrogate biomarkers 
in monitoring treatment response in clinical trials of novel therapeutic 
agents[12].
The aims of this study were: 1) to establish the feasibility of 
acquiring a measure of enhancing fraction based on changes in signal 
intensity (EnFSI); 2) to compare this with the more established IAUC60 
(both EnFIAUC60>0 and EnFIAUC60>2.5) based technique and 3) to assess the 
relationship of different measurements of EnF with survival in a cohort 
of GBM patients.
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Methods
Patients
The study had local ethical approval from the North-West 
Manchester Research and Ethics Committee and all patients provided 
written informed consent prior to imaging. All methods were performed 
in accordance with the relevant guidelines and regulations. Patients 
were identified via the weekly neuro-oncology multi-disciplinary team 
meetings at Salford Royal NHS Foundation Trust and inclusion criteria 
included patients over the age of 18 years with subsequent histologically 
confirmed grade IV GBM according to World Health Organisation 
(WHO) criteria. All imaging was performed prior to surgery. All 
patients received corticosteroids treatment for a minimum of 48 hours 
prior to imaging as the sole form of treatment prior to imaging. The 
minimum time period of 48 hours was chosen to ensure the steroid 
effects on perfusion/enhancement had plateaued by the point of 
imaging. Exclusion criteria included patients with contra-indication 
to MRI of any sort, poor renal function (contra-indicating gadolinium 
administration) and subsequent failure to have confirmatory diagnosis 
of GBM on histology.
Data acquisition
Imaging was performed on 3 Tesla Philips Achieva system (Philips 
Healthcare, Best, Netherlands) at the University of Manchester 
Magnetic Resonance Imaging Facility (Salford Royal Foundation Trust 
Hospital, Salford), using a SENSE 8-channel head coil. The DCE-MRI 
protocol images were acquired in a sagittal oblique orientation, which 
incorporated the internal carotid artery for measurement of an arterial 
input function (AIF) during the dynamic sequence and provided 
geometrically matched pre and post contrast T1-weighted sequences 
for definition of the tumour volume of interest (VOItumour_coregoblique). 
In addition, axial pre and post contrast T1-weighted sequences were 
acquired in keeping with our institution’s routine tumour imaging 
protocol. Sequences included: 1) An axial pre contrast T1-weighted 
spin echo sequence (TR 10 ms, TE 500 ms, slice thickness 4.0 mm, 256 
x 256 matrix). 2) A sagittal oblique pre contrast T1-weighted sequence 
(TR 9.3 ms, TE 4.6 ms, slice thickness 4.2 mm, 128 x 128 matrix). 3) 
Three sagittal oblique pre-contrast spoiled fast field echo (T1-FFE 
spoiled gradient echo) sequences with different flip angles (2˚, 10˚ 
and 16˚) for calculation of baseline T1 maps (TR 3.5 ms, TE 1.1 ms, 
slice thickness 4.2 mm, 128 x 128 matrix) using the standard variable 
flip angle relationship [13]. 4) A sagittal oblique dynamic, contrast 
enhanced acquisition series with identical acquisition parameters as the 
variable flip angle baseline T1 measurement, consisting of 100 volumes 
with temporal spacing of approximately 3.4 seconds. Gadolinium-
based contrast agent (Gd-DTPA-BMA; Omniscan, GE Healthcare, 
Oslo, Norway) was injected as a bolus of 3 ml, at 15 mls-1, at a dose of 
0.1 mmolkg-1 of body weight after acquisition of the fifth image volume. 
5) A sagittal oblique post contrast T1-weighted sequence (TR 9.3 ms, 
TE 4.6 ms, slice thickness 4.2 mm, 128 x 128 matrix). 6) An axial post 
contrast T1-weighted spin echo sequence (TR 10 ms, TE 500 ms, slice 
thickness 4.0 mm, 256 x 256 matrix)
All sagittal oblique acquisitions were co-aligned at the point of data 
acquisition.
Data analysis
VOIs were manually defined by an experienced radiologist (SJM) 
using a technique which has previously shown good inter-observer 
agreement (Intraclass Correlation Coefficient > 0.94) [14] VOIs 
(Figure 1) included a tumour VOI on the sagittal oblique post contrast 
T1-weighted image (VOItumour_coregoblique), a tumour VOI on the axial post 
contrast T1-weighted image (VOItumour_coregaxial) and a VOI of contralateral 
normal appearing white matter (NAWM) on the axial post contrast T1-
weighted image (VOINAWM_axial). A slice including the internal carotid 
artery was identified by the same radiologist to allow the generation of 
automated arterial input functions for the DCE-MRI analysis [15]. Post 
processing analysis was performed using in-house software (MaDyM – 
Manchester Dynamic Modelling) and the extended Tofts and Kermode 
pharmacokinetic model [16] and parametric maps of IAUC60 were 
generated. 
MATLAB (The Mathworks, Natick, Massachusetts, USA) was 
used for calculating all measures of enhancing fraction. For each 
tumour EnFIAUC60>0 was calculated by dividing the volume of voxels 
with an IAUC60 > 0 mMol.s by the total volume of the VOItumour_coregoblique. 
EnFIAUC60>2.5 was calculated by dividing the volume of voxels with an 
IAUC60 > 2.5 mMol.s by the total volume of the VOItumour_coregoblique. The 
change in signal intensity between pre and post contrast imaging was 
calculated for all voxels in both VOItumour_axial and VOINAWM_axial. EnFSI 
was calculated by measuring the volume of voxels with enhancement 
greater than the mean change in signal intensity in NAWM + 2 standard 
deviations, divided by the total volume of voxels in the VOItumour_axial.
Statistical analysis
All statistical analysis was performed using SPSS version 15.0 (SPSS 
Inc., Chicago, USA). Scatter plots of EnFIAUC60>0 and EnFIAUC60>2.5 versus 
EnFSI were generated. Agreement between the two measures of EnF 
(EnFIAUC60>0 and EnFIAUC60>2.5 versus EnFSI) were assessed with Bland-
Altman plots and a paired t-test on the mean observed differences 
between the two measures versus a mean difference of zero was 
performed to assess the probability of inherent bias in one method as 
compared with standard [17,18]. In addition, intraclass correlation 
analysis was performed as an alternative method of comparing the 
methodologies [19]. A further analysis of the relationship with all 
Figure 1. Scatter plot of EnFIAUC60>0 (blue circles) and EnFIAUC60>2.5 (red triangles) versus 
EnFSI for all patients. There is a significant correlation between EnFSI and both DCE-MRI 
derived parameters (EnFIAUC60>0:  = 0.870, p < 0.001 and R2 = 0.818 and EnFIAUC60>2.5:  = 
0.744, p < 0.001 and R2 = 0.642). 
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measures of EnF, age, pre-surgical tumour volume, treatment (initial 
chemoradiotherapy versus palliative radiotherapy) and patient survival 
using a multivariate Cox regression analysis was performed on a subset 
of patients with newly presenting GBM. Patients with recurrent GBM 
were excluded.
The datasets generated during and/or analysed during the current 
study are available from the corresponding author on reasonable 
request.
Results
30 patients were included in the initial aspect of the study, 
comparing the different methods of EnF measurement (11 female, 19 
males, mean age 59 years, age range 18-76 years). In the subsequent 
survival analysis, 1 patient with recurrent GBM was excluded. 1 patient 
was lost to follow up, but included in the analysis and censored, in 
accordance with standard Cox regression survival analysis.
The scatter plots for both EnFIAUC60>0 and EnFIAUC60>2.5 versus EnFSI 
are shown in Figure 1 and the Bland Altman plots in Figure 2. The 
results for the Bland Altman analysis are presented in Table 1. For 
EnFIAUC60>0 versus EnFSI, the paired t-test demonstrated a significant 
difference between the mean difference between measures and a mean 
difference of zero, p = 0.011. For EnFIAUC60>2.5 versus EnFSI, the paired 
t-test demonstrated a significant difference between the mean difference 
between measures and a mean difference of zero, p <0.001). Excellent 
intraclass correlation coefficients were demonstrated between EnFSI 
and both IAUC60 based measurements of EnF (EnFIAUC60>0 ICC = 0.909 
and EnFIAUC60>2.5 ICC = 0.883), indicating ‘almost perfect’ consistency 
of between EnFSI and EnFIAUC60>0 [19]. EnFSI had a tendency to measure 
slightly lower than EnFIAUC60>0 and markedly higher than EnFIAUC60>2.5 
(Figure 1). The lowest values of EnFIAUC60>0 (less than approximately 
0.60) demonstrated the greatest discrepancy between EnFIAUC60>0 and 




Figure 2. Bland Altman Plot of Average Enhancing Fraction determined by a) EnFIAUC60>0 and EnFSI versus the mean difference (EnFIAUC60>0 minus EnFSI) between the two measures and b) 
EnFIAUC60>2.5 and EnFSI versus the mean difference (EnFIAUC60>2.5 minus EnFSI) between the two measures.
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The Cox multivariable analysis results are shown in table 1. Only 
EnFIAUC60>0 (p=0.008) and age (p=0.01) demonstrated significant 
relationships with overall survival (Figure 3). A trend was seen with 
increasing EnFSI and patient survival, but this failed to reach significance 
(p = 0.061, Figure 4). Survival did not differ between patients receiving 
chemoradiotherapy or palliative radiotherapy (p=0.261). Neither pre-
treatment tumour volume or patient age demonstrated a significant 
relationship with survival (p=0.101 and p=0.15, respectively).
Discussion
EnF is a relatively recently described parameter [2,3,20,21]. A CT 
variant of this measure has shown potential in predicting disease free 
survival and time to progression in patients with ovarian carcinoma [1]. 
The technique used in this study was simple, using only post contrast 
CT images and calculating EnF by classifying voxels as enhancing if 
the Hounsfield unit measure for a given voxel was greater than a set 
threshold. A number of patients with cerebral tumours will have a CT 
scan as their initial investigation, but the imaging modality of choice for 
brain tumour characterisation is an MRI scan and therefore the ability 
to derive a signal intensity based MRI measure of EnF was assessed 
in the current study as opposed to a CT based measure. A study of 
DCE-MRI derived EnF in glioma has shown the use of thresholding 
allows the distinction between histological grade of tumour [3]. In the 
unthresholded form, EnFIAUC60>0 correlated with vp in low grade tumours 
and Ktrans in GBM [2]. These latter studies have all required a DCE-




Figure 3. Scatter plot of a) EnFIAUC60>0 and patient survival, linear regression analysis shows increased survival with increased EnFIAUC60>0 (p=0.008) and b) EnFSI and patient survival. A non-
significant trend is seen with increased survival with increased EnFSI (p=0.061).
Parameter Cox Multivariate Significance Level (p=)






Table 1. Cox multivariate significance levels for relationship between parameters and 
patient overall survival. ** Significance taken as p<0.01
Mills SJ (2017) Survival and enhancing fraction (EnF) in glioblastoma multiforme (GBM)
 Volume 1(3): 5-6Radiol Diagn Imaging, 2017          doi: 10.15761/RDI.1000118
of this research into the clinical setting. The ability to derive EnF from 
conventional pre and post contrast weighted imaging makes it a much 
more attractive parameter for clinical use. This study demonstrates that 
it is feasible to obtain a signal intensity based measure of EnF from 
routine conventional imaging, which is comparable with that derived 
from DCE-MRI data. 
The EnF measures are not directly interchangeable; EnFSI having 
a tendency to measure slightly lower than EnFIAUC60>0 and markedly 
higher than EnFIAUC60>2.5 (Figure 1). This likely reflects the difference 
in thresholding between the techniques. The EnFIAUC60>0 metric has no 
thresholding applied at all and merely identifies a voxel as enhancing 
due to contrast agent being measurable. EnFSI is thresholded relative 
to NAWM, thereby a voxel is only considered to be enhancing if 
there is an increase in T1 signal intensity that is greater than would be 
expected in NAWM. EnFIAUC60>2.5 is thresholded to a level that provides 
maximum discrimination between grade II and grade IV gliomas. 
Other groups have previously used signal intensity based measures 
to assess enhancement in glial tumours [22-24] but these have 
predominantly focused on assessing the intensity of enhancement, 
rather than the proportion of enhancement. Serial studies of such 
metrics have shown potential in predicting which low grade gliomas 
will subsequently undergo malignant transformation [24] and, in 
high grade gliomas, have been shown to correlate with the volume 
of surrounding oedema [23]. Unlike the thresholded measure of EnF 
(EnFIAUC60>2.5) these measures do not distinguish between histological 
grade of tumour [3,22]. Studies of subjective semi-quantitative [25,26] 
and planimetry volume [27] measures of tumour “necrosis”, defined 
as non-enhancement, have shown shorter survival in patients with 
larger necrotic volumes, and this is concordant with our findings. 
More recently, the change in T1 signal measured on conventional post 
contrast sequences on serial imaging in bevaziumab treated recurrent 
GBM has shown value in predicting disease progression [28].
There are potential limitations in using a signal intensity based 
method for calculating EnF. Unlike CT, the relationship between 
signal intensity and contrast agent concentration on MRI is nonlinear. 
However, the measurement of EnF does not require an estimation of 
the degree of intensity of enhancement, but merely a binary measure 
of whether it is present or not in order to calculate the proportion 
of tumour that enhances. Normalising the change in signal intensity 
with that seen in contralateral NAWM improves the specificity so that 
only changes in signal intensity greater than those seen in NAWM 
are classified as enhancing. This normalisation technique should also 
help overcome variations in signal intensity that may occur between 
subjects, scanners, acquisition sequences and centres.
In this study, EnFIAUC60>0 alone demonstrated a significant 
relationship with overall patient survival and this was irrespective of 
treatment, pre-operative tumour volume and age. The lack of a difference 
in survival between full chemoradiotherapy regime and palliative 
radiotherapy alone is interesting. This may reflect an unconscious bias 
by the clinicians to palliate patients with larger, more necrotic tumour 
rather than subject those individuals to a full chemoradiotherapy 
regime, although no relationship between pre-operative tumour 
volume and survival was found in our small study. A trend of increasing 
EnFSI and prolonged survival was noted but failed to reach significance. 
There are a number of differences between these two EnF measures. 
EnFSI is normalised to contralateral normal appearing white matter, 
and is therefore more likely to represent pathological ‘enhancement’ 
as any ‘enhancement’ similar to that seen in normal brain is excluded 
as ‘non-enhancing’. Due to the technique and post-processing analysis 
for measurement EnFIAUC60>0, no normalisation with contralateral 
normal appearing white matter could be made, therefore measurement 
of EnF via this method classifies voxels as enhancing if they contain 
any contrast agent within them, even within the normal vascular space 
(as in normal brain tissue) and therefore may give a higher measure 
of EnF when compared to a technique which is adjusted to normal 
brain tissue. Furthermore, the EnFIAUC60>0 parameter is obtained from 
a volumetric dataset, whilst the EnFSI is derived from non-volumetric 
4 mm conventional imaging slices. No attempt was made during the 
conventional imaging acquisition to overcome the automatic scanner 
gain function and therefore variability in the measures of signal 
intensity may have occurred between pre and post contrast imaging for 
each patient, but this is unlikely to have had a significant impact thanks 
to the test for signal intensity enhancement difference from NAWM, 
which provides normalisation for changes of intensity scale. The failure 
for EnFSI, unlike EnFIAUC60>0, to significantly relate to survival, may 
reflect the small number of patients in this current study. Whilst DCE-
derived EnF is likely to be a more robust and reliable parameter than 
EnFSI, EnFSI has the advantage of being available from conventional 
pre and post contrast T1-weighted sequences which are part of routine 
clinical imaging and do not require additional T1 mapping sequences 
and a DCE-acquisition and the associated complex pharmaco-kinetic 
post-processing making this technique a more desirable tool for the 
routine clinical setting. 
Our findings differ from that reported by Gutman et al., in a 
study of 75 pre-surgical GBM, they found that visual assessment 
of proportional contrast enhancement showed worse survival with 
increasing proportional enhancement with a hazards ratio of 7.745[29]. 
Proportional enhancement in this study was catergorised subjectively 
as 0-5%, 6-33%, 34-67%, 68-95% and 95-100% by a variety of 
neuroradiologists, and included the surrounding oedema as part of the 
whole tumour volume. This differs from the work presented in this study 
whereby quantitative rather than categorical volumetric assessment 
was performed, by a single radiologist using a technique, which has 
previously shown good intra and inter-observer variability [14], and 
the surrounding T2 signal abnormality/oedema was not included in 
the whole tumour volume. A larger quantitative volumetric analysis 
of 94 GBM by the same group also reported increased proportional 
enhancement was associated with increased mortality (p=0.003), but 
as with the previously study included the perilesional T2 and FLAIR 
signal abnormality as part of the whole tumour volume [30]. Perez-
Beteta et al. assessed the pre-treatment geometry in 117 patients with 
GBM and reported both increases in tumour volume and contrast 
enhancing volume were associated with reduced overall survival 
(p=0.034, hazards ratio 1.574 and p=0.017, hazards ratio 1.659), but no 
assessment of the proportional enhancement of the tumour was made 
in this study [31].
Conclusion
This study demonstrates that a measure of proportional 
enhancement can be derived from conventional pre and post contrast 
enhanced MR imaging. Whilst EnFSI demonstrates a significant 
correlation with EnF derived from DCE-MRI data, both EnFIAUC60>0 and 
EnFIAUC60>2.5, the two measures are not directly interchangeable. Only 
EnFIAUC60>0 related to patient survival, with higher values associated 
with prolonged survival. A similar non-significant trend was seen with 
the signal intensity based metric of EnF.
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